Postoperative NEOadjuvant TEMozolomide followed by chemoradiotherapy versus upfront chemoradiotherapy for glioblastoma multiforme (NEOTEM) trial: Interim results.
Saved in:
| Title: | Postoperative NEOadjuvant TEMozolomide followed by chemoradiotherapy versus upfront chemoradiotherapy for glioblastoma multiforme (NEOTEM) trial: Interim results. |
|---|---|
| Authors: | Sharifian A; Department of Radiation Oncology, Cancer Institute, IKHC, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Kazemian A; Radiation Oncology Research Center, Cancer Research Institute, IKHC, Tehran University of Medical Sciences, Tehran, Iran.; Department of Radiation Oncology, Cancer Institute, IKHC, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Farzin M; Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.; Department of Radiation Oncology, Cancer Institute, IKHC, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Amirkhani N; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Farazmand B; Radiation Oncology Research Center, Cancer Research Institute, IKHC, Tehran University of Medical Sciences, Tehran, Iran., Naderi S; Department of Neurosurgery, Iran University of Medical Sciences, Tehran, Iran., Khalilian A; Radiation Oncology Research Center, Cancer Research Institute, IKHC, Tehran University of Medical Sciences, Tehran, Iran.; Department of Radiation Oncology, Cancer Institute, IKHC, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Pourrashidi A; Department of Neurosurgery, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran., Amjad G; UPMC Hillman Cancer Center, Radiology Department, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Kolahdouzan K; Radiation Oncology Research Center, Cancer Research Institute, IKHC, Tehran University of Medical Sciences, Tehran, Iran.; Department of Radiation Oncology, Cancer Institute, IKHC, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Abyaneh R; Radiation Oncology Research Center, Cancer Research Institute, IKHC, Tehran University of Medical Sciences, Tehran, Iran., Jablonska PA; Radiation Oncology Department, Hospital Universitario de Navarra, Pamplona, Spain., Ghalehtaki R; Radiation Oncology Research Center, Cancer Research Institute, IKHC, Tehran University of Medical Sciences, Tehran, Iran.; Department of Radiation Oncology, Cancer Institute, IKHC, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. |
| Source: | Neuro-oncology advances [Neurooncol Adv] 2024 Nov 14; Vol. 6 (1), pp. vdae195. Date of Electronic Publication: 2024 Nov 14 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 101755003 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-2498 (Electronic) Linking ISSN: 26322498 NLM ISO Abbreviation: Neurooncol Adv Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
